170 related articles for article (PubMed ID: 31744788)
1. Role of
Budak E; Yanarateş A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):14-19. PubMed ID: 31744788
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
Kaya AO; Coskun U; Unlu M; Akdemir UO; Ozdemir NY; Zengin N; Benekli M; Yildiz R; Yaman E; Ozturk B; Gumus M; Uner A; Yamac D; Ucgul E; Buyukberber S
Asian Pac J Cancer Prev; 2008; 9(4):683-6. PubMed ID: 19256759
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
6. The impact of 18F-FDG PET/CT in the clinical management of patients with lymph node metastasis of unknown primary origin.
Nikolova PN; Hadzhiyska VH; Mladenov KB; Ilcheva MG; Veneva S; Grudeva VV; Dineva SE; Asenov YN
Neoplasma; 2021 Jan; 68(1):180-189. PubMed ID: 32880466
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of diffusion-weighted imaging and
Noij DP; Martens RM; Zwezerijnen B; Koopman T; de Bree R; Hoekstra OS; de Graaf P; Castelijns JA
Eur J Radiol; 2018 Oct; 107():20-25. PubMed ID: 30292267
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors.
Al-Bulushi NK; Abouzied ME
Nucl Med Commun; 2016 Jun; 37(6):583-8. PubMed ID: 26813992
[TBL] [Abstract][Full Text] [Related]
9. Value of 18F-FDG PET/CT in patients with hepatic metastatic carcinoma of unknown primary.
Li Y; Li F; Li X; Qu L; Han J
Medicine (Baltimore); 2020 Dec; 99(50):e23210. PubMed ID: 33327238
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of
Caspersen KB; Giannoutsou N; Gerke O; Alavi A; Høilund-Carlsen PF; Hess S
Ann Nucl Med; 2019 Mar; 33(3):184-192. PubMed ID: 30569441
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
13. [(18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin].
Hu M; Li MH; Kong L; Liu NB; Yang GR; Yu JM
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):699-701. PubMed ID: 19173915
[TBL] [Abstract][Full Text] [Related]
14. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
15. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
[TBL] [Abstract][Full Text] [Related]
16. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Value of Whole-Body DWI With Background Body Suppression Plus Calculation of Apparent Diffusion Coefficient at 3 T Versus
Sun W; Li M; Gu Y; Sun Z; Qiu Z; Zhou Y
AJR Am J Roentgenol; 2020 Feb; 214(2):446-454. PubMed ID: 31799866
[No Abstract] [Full Text] [Related]
18. Sensitivity of [18F]FDG PET/CT and classification of the primary tumor site in patients with carcinoma of unknown primary.
Atilgan HI; Yalcin H
Nucl Med Rev Cent East Eur; 2022; 25(1):1-5. PubMed ID: 35137930
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of
Wolpert F; Weller M; Berghoff AS; Rushing E; Füreder LM; Petyt G; Leske H; Andratschke N; Regli L; Neidert MC; Stupp R; Stahel R; Dummer R; Frauenfelder T; Roth P; Reyns N; Kaufmann PA; Preusser M; Le Rhun E
Eur J Cancer; 2018 Jun; 96():64-72. PubMed ID: 29677642
[TBL] [Abstract][Full Text] [Related]
20. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary.
Paul SA; Stoeckli SJ; von Schulthess GK; Goerres GW
Eur Arch Otorhinolaryngol; 2007 Feb; 264(2):189-95. PubMed ID: 17177026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
